About Scancell
Scancell is a company based in Nottingham (United Kingdom) founded in 1997. It operates as a HealthTech. Scancell has raised $5.84 million across 12 funding rounds from investors including Calculus Capital, Oxford Technology and UK Research and Innovation. Scancell offers products and services including iSCIB1+ and Moditope Peptide Therapy. Scancell operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Nottingham, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Scancell Holdings Plc
-
Annual Revenue
$6.29 M (USD)0as on Apr 30, 2025
-
Net Profit
$-16.38 M (USD)-109.46as on Apr 30, 2025
-
EBITDA
$-18.85 M (USD)18.37as on Apr 30, 2025
-
Total Equity Funding
$5.84 M (USD)
in 12 rounds
-
Latest Funding Round
$14.41 M (USD), Post-IPO
Dec 10, 2024
-
Investors
Calculus Capital
& 5 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Scancell
Scancell is a publicly listed company on the LSE with ticker symbol SCLP in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Scancell
Scancell offers a comprehensive portfolio of products and services, including iSCIB1+ and Moditope Peptide Therapy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
An Immunobody DNA therapy for advanced melanoma treatment.
A peptide therapy targeting various solid tumor cancers.
Unlock access to complete
Unlock access to complete
Funding Insights of Scancell
Scancell has successfully raised a total of $5.84M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $14.41 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Post-IPO — $14.4M
-
First Round
First Round
(01 Dec 2003)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Post-IPO - Scancell | Valuation |
investors |
|
| Oct, 2020 | Amount | Post-IPO - Scancell | Valuation |
investors |
|
| Aug, 2020 | Amount | Grant - Scancell | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Scancell
Scancell has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Calculus Capital, Oxford Technology and UK Research and Innovation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
UK venture capital investments are managed by Calculus Capital.
|
Founded Year | Domain | Location | |
|
Early-stage venture capital is invested in UK technology sectors.
|
Founded Year | Domain | Location | |
|
Early-stage micro-VC investments are focused on UK companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Scancell
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Scancell
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Scancell Comparisons
Competitors of Scancell
Scancell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Scancell
Frequently Asked Questions about Scancell
When was Scancell founded?
Scancell was founded in 1997 and raised its 1st funding round 6 years after it was founded.
Where is Scancell located?
Scancell is headquartered in Nottingham, United Kingdom.
Is Scancell a funded company?
Scancell is a funded company, having raised a total of $5.84M across 12 funding rounds to date.
What is the annual revenue of Scancell?
Annual revenue of Scancell is $6.29M as on Apr 30, 2025.
What does Scancell do?
Scancell is engaged in the development of active immunotherapies aimed at treating cancer by enhancing long-lasting tumor-specific immunity. The company utilizes proprietary platforms such as Immunobody and Moditope to create potent therapies for hard-to-treat cancers. Solutions like iSCIB1 target advanced melanoma with safe and effective immune responses, while Moditope therapies address a broad range of solid tumors. The focus remains on delivering patient-accessible treatments that transform cancer care standards across the healthcare sector.
Who are the top competitors of Scancell?
Scancell's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Scancell offer?
Scancell offers iSCIB1+ and Moditope Peptide Therapy.
Is Scancell publicly traded?
Yes, Scancell is publicly traded on LSE under the ticker symbol SCLP.
Who are Scancell's investors?
Scancell has 6 investors. Key investors include Calculus Capital, Oxford Technology, UK Research and Innovation, Seneca Growth Capital, and Redmile Group.
What is Scancell's ticker symbol?
The ticker symbol of Scancell is SCLP on LSE.